Blog
RSS FeedPosted by Michael Wonder on 13 Jul 2025
Delgocitinib for the treatment of patients with moderate to severe chronic hand eczema
8 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 13 Jul 2025
Zanubrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma
10 July 2025 - NICE has published final evidence-based recommendations on the use of zanubrutinib for the treatment of adults ...
Posted by Michael Wonder on 10 Jul 2025
Albanese should consider tweaks to PBS to avoid Trump tariff: CSL chair
9 July 2025 - Donald Trump’s move to ramp up tariffs on medicines and copper has sparked alarm among government ...
Posted by Michael Wonder on 09 Jul 2025
PBS ‘not on the table’ in battle for pharmaceutical tariff exemption, despite lobbying
9 July 2025 - The threat of global 200 per cent tariffs on pharmaceutical products presents a challenge to Australia’s drug ...
Posted by Michael Wonder on 07 Jul 2025
Will miracle HIV drug go on the PBS?
5 July 2025 - A new twice yearly antiviral injection that can prevent HIV is likely to be approved soon in ...
Posted by Michael Wonder on 06 Jul 2025
Garadacimab for the prevention of recurrent attacks of hereditary angioedema in patients 12 years of age and older
2 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Jul 2025
Quebec implements public reimbursement of Pluvicto - a defining milestone for radioligand therapy in Canada
3 July 2025 - Pluvicto now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA ...
Posted by Michael Wonder on 05 Jul 2025
Teprotumumab for the treatment of patients with thyroid eye disease
2 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 04 Jul 2025
Public Summary Documents - March 2025 PBAC meeting
4 July 2025 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the March 2025 ...
Posted by Michael Wonder on 03 Jul 2025
Release of provisional recommendations for expert advisory committees
1 July 2025 - We’re improving our processes, so that people can understand the outcome of expert advice to PHARMAC earlier. ...
Posted by Michael Wonder on 03 Jul 2025
Top level push for taxpayer funding of weight loss drugs gathers pace
3 July 2025 - Pharma giants are sweating on the results of a federal government request for guidance on adding weight ...
Posted by Michael Wonder on 03 Jul 2025
Big pharma calls out Australia’s ‘freeloading’ on US medicine
3 July 2025 - American pharmaceutical manufacturers have ramped up pressure on Donald Trump to take action against Australia over its ...
Posted by Michael Wonder on 02 Jul 2025
Calls for 'missing piece' menopause drug to be added to the PBS
2 July 2025 - A key treatment which could help around one million middle-aged Australian women remains unaffordable to many ...
Posted by Michael Wonder on 02 Jul 2025
Life-saving breast cancer drug now cheaper thanks to expansion of the PBS
1 July 2025 - A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...
Posted by Michael Wonder on 02 Jul 2025
Adagrasib for adults with previously treated, advanced, KRAS G12C mutation positive non-small-cell lung cancer
2 July 2025 - NICE is unable to make a recommendation on the use of adagrasib (Krazati) for the second-line treatment ...